Best Peptides for Recovery

This guide reflects our 2026 review of the preclinical and clinical literature. We match each peptide to a repair pathway by mechanism and the strength of its evidence base, rather than by reputation.

Key Takeaways

• Recovery peptides act on distinct tissue-repair pathways; mechanism-matching is more useful than ranked lists.
• BPC-157, TB-500, GHK-Cu, MOTS-c, and CJC-1295 + Ipamorelin each target different repair endpoints (angiogenesis, cell migration, collagen remodelling, mitochondrial recovery, GH-axis signalling).
• None hold MHRA marketing authorisation; all are supplied strictly for laboratory research use in the UK.
• Human trial data remain limited; most evidence comes from rodent and in vitro models as of 2026.
• Dose-validated multi-dose pen formats reduce reconstitution variance across study arms.

---

The best peptides for recovery research in the UK in 2026 are selected by tissue-repair mechanism, not by ranked lists: BPC-157 for cytoprotection and angiogenesis, TB-500 (thymosin β4) for cell migration and systemic repair, GHK-Cu for collagen remodelling, MOTS-c for mitochondrial recovery, and CJC-1295 + Ipamorelin for GH-axis signalling [1][6][7][12]. Each acts on a distinct repair pathway, which is why mechanism-matching beats generic ranking.

None of these compounds hold an MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation; all are supplied strictly for laboratory research use in the UK [3][8]. Human trial data remain limited. BPC-157 and TB-500, including the popular "Wolverine" blend, are still backed primarily by rodent and in vitro models, with no published Phase II/III musculoskeletal randomised controlled trials (RCTs) as of 2026 [2][5].

What this guide covers

This guide explains how to match recovery peptides to specific tissue-repair pathways, profiles five compounds (BPC-157, TB-500, GHK-Cu, MOTS-c, CJC-1295/Ipamorelin), covers 2026 UK regulatory status and WADA position, and outlines how dose-validated multi-dose pen formats reduce research variance. The final section offers a decision framework for selecting the right peptide for your research endpoint.

Top Picks: Best Recovery Peptides for Research (2026)

Recovery is a multi-pathway problem, so our top picks are ranked as best-in-class for each repair pathway rather than as a single overall winner. Each pick is a catalogued Body Pharm UK research peptide, supplied for laboratory and analytical use only.

• Best overall / most complete soft-tissue mechanism — BPC-157 + TB-500 blend. The most-requested recovery stack, pairing BPC-157's local cytoprotection and VEGF-mediated angiogenesis with TB-500's systemic actin-driven cell migration, covering complementary phases of tissue repair in one pen.
• Best for mitochondrial / metabolic recovery — MOTS-c. The mitochondrial-derived peptide that activates AMPK and modulates metabolic gene expression (Lee et al., 2021), the reference tool for post-exercise mitochondrial-fatigue and metabolic-recovery models.
• Best for GH-axis recovery signalling — CJC-1295 + Ipamorelin. A GHRH analogue plus selective ghrelin mimetic studied for pulsatile GH/IGF-1 release relevant to anabolic signalling and slow-wave-sleep recovery.
• Best for collagen / dermal remodelling — GHK-Cu. The copper-tripeptide standard for collagen synthesis and anti-inflammatory ECM remodelling, the natural complement to a structural-repair arm.

Read these as pathway-anchored picks: the right choice is the one whose mechanism matches the tissue and endpoint you are modelling. The decision matrix below maps every compound to its repair pathway in full.

What Are Recovery Peptides? (2026 Overview)

Recovery peptides are short synthetic or naturally derived amino-acid sequences studied in preclinical models for tissue repair, angiogenesis, cytoprotection, and mitochondrial recovery, rather than for acute performance enhancement [1][2]. They differ from performance peptides such as GH-axis secretagogues used primarily for hypertrophy or fat loss, although CJC-1295 and Ipamorelin sit at the overlap because of their indirect role in repair via GH/IGF-1 signalling [12][13].

As of 2026, none of the peptides covered here (BPC-157, TB-500, GHK-Cu, MOTS-c, CJC-1295, Ipamorelin) hold an MHRA marketing authorisation for human therapeutic use in the UK [3]. They are supplied strictly for in vitro and laboratory research, and UK vendors must avoid medicinal claims to remain compliant [3][6].

The current evidence base is preclinical. BPC-157 and TB-500 are the two most-cited soft-tissue repair peptides in rodent and in vitro literature, with no published Phase II/III musculoskeletal RCTs in humans as of 2026 [2][9].

Defining features of a recovery peptide

• Mechanism-led: acts on a defined repair pathway (e.g. VEGF (vascular endothelial growth factor)-mediated angiogenesis for BPC-157, actin-sequestration for TB-500) [1][10].
• Preclinical evidence base: supported primarily by rodent and in vitro models, not human RCTs [2][9].
• Unlicensed in the UK: no MHRA marketing authorisation; research-use-only supply [3].
• WADA-prohibited in-competition where they fall under peptide hormone or growth factor classes [3].

For a direct head-to-head on the two most-researched soft-tissue agents, see BPC-157 vs TB-500: recovery peptides compared.

Repair Pathway Decision Matrix: Which Peptide for Which Research Goal?

Mechanism-matching is the most useful filter when selecting recovery peptides. Each compound acts on a distinct tissue-repair pathway, and the wrong choice will produce null results regardless of dose. The matrix below maps the six most-researched recovery peptides (plus NAD+) to their primary mechanism, the tissue with the strongest preclinical evidence, and the supplied format at Body Pharm UK as of 2026.

How to read the matrix

Read across, not down. A researcher modelling Achilles tendon repair should anchor on BPC-157 because tendon is the tissue with the densest preclinical signal for that compound [3], not because BPC-157 tops a generic list. A researcher modelling exercise-induced mitochondrial dysfunction should anchor on MOTS-c because the Lee et al. 2021 Nature Metabolism paper establishes the mitochondrial-AMPK pathway as its primary site of action [11].

Why mechanism-matching matters for research design

Pairing decisions follow the same logic. The BPC-157 + TB-500 blend is the most commercially requested combination in UK research peptide sales as of 2026, but no peer-reviewed combination study has been published [5], so any protocol using it should be framed as hypothesis-driven. For a direct head-to-head, see BPC-157 vs TB-500: recovery peptides compared; for dosing schedules once the blend is selected, see how to dose BPC-157 + TB-500.

BPC-157: The Most-Researched Soft-Tissue Repair Peptide

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective sequence in human gastric juice. It is the most-cited recovery peptide in preclinical soft-tissue repair literature because rodent models consistently show accelerated tendon, ligament, and gut-lining healing via VEGF upregulation and nitric oxide pathway modulation [1][2].

Mechanism and preclinical evidence base

The foundational mechanism work by Sikiric and colleagues, consolidated in their 2018 Current Pharmaceutical Design review, established that BPC-157 promotes angiogenesis through VEGFR2 activation, stabilises endothelial integrity, and accelerates tendon-to-bone reattachment in transected rodent Achilles models [1]. Subsequent rodent work extended the signal to medial collateral ligament transection, segmental colitis, and gastric ulcer models, which is why researchers modelling connective-tissue injury tend to anchor on this compound rather than systemic alternatives [1][2].

Human clinical trial data as of 2026 remain limited. No peer-reviewed Phase II or III musculoskeletal trial has reported outcomes, and 2024-2025 reviews continue to describe BPC-157 as an investigational peptide supported primarily by rodent and in vitro data [2][3]. Any UK research protocol should be designed with that evidence ceiling in mind.

What to look for in a UK research-grade supply

When evaluating BPC-157 for a tissue-repair study, five supply characteristics matter:

• Sequence purity verified by HPLC (high-performance liquid chromatography) at ≥98%, with a batch certificate available before dispatch.
• Dose accuracy across repeat subcutaneous injection administrations, which is where lyophilised vial reconstitution introduces the most variance.
• Stability data for the reconstituted solution under standard 2-8 °C storage.
• Format suitability for the protocol, covering single-injection vial work versus repeat dosing across a 4-8 week study arm.
• Blend availability if the research design pairs BPC-157 with TB-500 for combined local plus systemic repair signalling [3][4].

Body Pharm UK supplies BPC-157 within the BPC-157 + TB-500 pen — a single co-dissolved cartridge holding 16 mg of each peptide in a fixed 50/50 blend — which removes reconstitution variance across repeat doses. The dial sets the dose of each peptide, so the total delivered is double the dialled figure. That is a meaningful design advantage for studies running longitudinal endpoints. For a direct mechanism comparison, see BPC-157 vs TB-500: recovery peptides compared, and for protocol design once the blend is selected, how to dose BPC-157 + TB-500.

TB-500 (Thymosin Beta-4): Angiogenesis and Soft-Tissue Repair

TB-500 is a thymosin beta-4 synthetic fragment that promotes actin polymerisation, endothelial cell migration, and angiogenesis in preclinical soft-tissue and cardiac repair models [2][4]. It is the systemic-repair counterpart most UK researchers pair with BPC-157's localised cytoprotective action.

Mechanism and what TB-500 actually is

TB-500 is not full-length thymosin beta-4. It is a synthetic analogue corresponding to the active region of the Tβ4 molecule (the Ac-SDKP-containing sequence), engineered for improved solubility and tissue penetration in research settings. The mechanistic interest centres on four actions:

• Actin sequestration and polymerisation, which supports cytoskeletal reorganisation during cell migration into wounded tissue.
• Upregulation of VEGF signalling, driving the angiogenic response in ischaemic or damaged muscle.
• Anti-inflammatory modulation at the injury site, reducing secondary tissue damage in rodent models of cardiac and skeletal-muscle injury.
• Recruitment of progenitor cells to areas of soft-tissue and connective-tissue damage.

The standing review reference for these mechanisms remains Goldstein and Kleinman's 2015 work on thymosin beta-4 biology in the Annals of the New York Academy of Sciences. Any TB-500 evidence published before 2023 should be treated as potentially stale for trial-quality endpoints, because no registered human tendon, ligament, or cardiac-repair trial reporting TB-500 outcomes has been published in the 2024-2026 window [2][4].

Why TB-500 is paired with BPC-157

The pairing rationale is mechanistic complementarity, not combination trial data. BPC-157 acts primarily on local cytoprotection and gut-derived repair signalling, whereas TB-500 acts systemically on angiogenesis and cell migration [3][4]. No peer-reviewed combination study with defined dosing and endpoints has been published, so the blend should be framed as hypothesis-driven rather than combination-validated [3].

For the head-to-head breakdown, see BPC-157 vs TB-500: recovery peptides compared, and for protocol planning once the blend is selected, how to dose BPC-157 + TB-500.

BPC-157 + TB-500 Blend: Why Researchers Combine Them

The BPC-157 + TB-500 blend is studied as a complementary-mechanism stack because each peptide acts on a distinct tissue regeneration pathway that the other does not cover [2][3]. BPC-157 drives local cytoprotection and VEGF-mediated angiogenic signalling at the injury site, while TB-500 (thymosin β4 synthetic fragment) acts systemically on actin sequestration, cell migration, and broader vascular remodelling [3][4].

The combined rationale, as framed in 2024-2026 practitioner and educational sources, is mechanistic rather than trial-validated [2][3]:

• Dual angiogenic coverage: BPC-157 upregulates VEGF locally; TB-500 promotes endothelial migration and capillary formation in ischaemic tissue [3][4].
• Cytoprotection plus cell migration: BPC-157 stabilises injured cells near the lesion; TB-500 mobilises progenitor cells from circulation into damaged connective tissue [3][4].
• Tendon and ligament repair model signal: pre-2023 rodent work on Achilles transection and medial collateral ligament injury reports faster fibroblast organisation under single-agent dosing for each peptide, which is the basis for the combination hypothesis [4].
• Gut-lining repair overlap: BPC-157 carries the densest gastric mucosal evidence, and TB-500's systemic angiogenic action is hypothesised to support enteric capillary recovery in the same models [1][4].

No combination RCTs exist as of 2026, so the blend is hypothesis-driven, not combination-validated [2][3].

Body Pharm UK blend pen format

The Body Pharm UK BPC-157 + TB-500 blend is supplied as a sealed, dose-validated multi-dose pen, dispatched discreetly across the UK for research and analytical purposes only. The pen format removes the reconstitution variance that affects vial-based research workflows: each click delivers a fixed microgram dose verified at batch level. That consistency is the practical reason researchers comparing multiple cohorts choose pen-format peptides over lyophilised vials.

For the single-agent breakdown, see BPC-157 vs TB-500: recovery peptides compared. For protocol planning once the blend is selected, see how to dose BPC-157 + TB-500.

MOTS-c: Mitochondrial Recovery Peptide (UK Research Overview)

MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S rRNA region of mitochondrial DNA. It is relevant to recovery research because it regulates nuclear gene expression in response to metabolic stress rather than acting on local tissue repair pathways [10]. That mechanism puts it in a different category from BPC-157, TB-500, and GHK-Cu, which target angiogenesis and cytoprotection at the lesion site.

Key points UK researchers should hold before designing a MOTS-c protocol:

• Mechanism: MOTS-c translocates to the nucleus under metabolic stress and modulates AMPK-linked gene expression governing glucose handling and mitochondrial biogenesis [10].
• Primary research endpoints: exercise-induced fatigue, insulin sensitivity, and metabolic recovery after sustained physical stress, as established in the Lee et al. 2021 Nature Metabolism mouse and human work [10].
• Not a GH-axis peptide: MOTS-c does not signal through GHRH or ghrelin receptors, so it does not overlap mechanistically with CJC-1295 or Ipamorelin and should not be substituted for them in GH-axis studies [10][11].
• Evidence base: smaller than BPC-157's, with Lee et al. 2021 still the foundational human reference and no large independent Phase II/III replication published by 2026 [10][11].

Where MOTS-c fits in a recovery research stack

MOTS-c is best framed as a systemic metabolic recovery candidate rather than a structural-repair peptide. That means it complements rather than replaces BPC-157 + TB-500 in models examining post-exercise mitochondrial fatigue. Body Pharm UK supplies MOTS-c in the same dose-validated multi-dose pen format used for the BPC-157 + TB-500 blend, removing reconstitution variance between cohorts and standardising microgram delivery across repeat-dose study arms.

CJC-1295 + Ipamorelin: GH-Axis Recovery Research

CJC-1295 + Ipamorelin is a paired GH-axis research blend: CJC-1295 is a GHRH analogue that extends GHRH signalling via its DAC (Drug Affinity Complex) modification, while Ipamorelin triggers a clean GH pulse through selective GHS-R (growth hormone secretagogue receptor) agonist activity [3][4]. The combination is studied for synergistic GH secretion relevant to anabolic signalling, slow-wave sleep architecture, and post-training recovery in preclinical models [3].

Mechanism split: why the pairing exists

CJC-1295 with DAC binds serum albumin to extend its half-life into the 6-8 day range described in the foundational Ionescu and Frohman 2006 Journal of Clinical Endocrinology & Metabolism pharmacokinetic study, which remains the primary PK reference as of 2026 with no superseding human PK trial published in the 2024-2026 window [3][4]. Ipamorelin is a selective GHS-R agonist that, in preclinical work, produces GH release without the cortisol or prolactin elevation associated with older secretagogues such as GHRP-6 [3].

Evidence base and regulatory status

Human trial data for the specific CJC-1295 + Ipamorelin combination remain limited in 2024-2026 indexed literature, with most contemporary commentary focused on stacking strategy rather than new pharmacodynamic measurements [3][4]. Both peptides are unlicensed in the UK and are handled as investigational research substances rather than MHRA-authorised medicines. Both also fall under WADA's prohibited peptide hormones and growth factors class in-competition [1][2].

Body Pharm UK 20mg combination pen

Body Pharm UK supplies CJC-1295 + Ipamorelin as a 20mg dose-validated multi-dose pen for subcutaneous injection research administration. This removes the reconstitution variance researchers encounter when pairing two separate lyophilised vials. Researchers comparing GH-axis signalling against structural-repair pathways often run this blend alongside a BPC-157 + TB-500 arm; see BPC-157 vs TB-500: recovery peptides compared for the structural-repair comparison and how to dose BPC-157 + TB-500 for the parallel dosing framework.

GHK-Cu and NAD+: Supporting Recovery Pathways

GHK-Cu (copper peptide) and NAD+ (nicotinamide adenine dinucleotide) are the two most commonly stacked non-primary recovery compounds because each targets a pathway the four headline peptides do not fully cover: extracellular matrix remodelling and collagen synthesis for GHK-Cu, intracellular redox and DNA repair for NAD+. Both are handled as research substances in the UK in 2026 and neither holds an MHRA marketing authorisation for injectable use [13].

GHK-Cu (copper tripeptide)

GHK-Cu is a glycyl-L-histidyl-L-lysine tripeptide bound to copper(II), studied since the 1970s for collagen and glycosaminoglycan synthesis, anti-inflammatory signalling, and wound-bed remodelling [13]. The Pickart and Margolina 2018 Biomolecules review remains the most-cited mechanistic summary, and 2024-2026 secondary literature has not superseded it with a comparably comprehensive update [13]. In the UK and EU, GHK-Cu is regulated principally as a topical cosmetic ingredient; no MHRA authorisation exists for injectable GHK-Cu, and vendors supply it strictly for laboratory research [13].

NAD+ (nicotinamide adenine dinucleotide)

NAD+ is a coenzyme rather than a peptide, but it is routinely studied alongside recovery peptides because it sits upstream of sirtuin activity, PARP (poly-ADP-ribose polymerase)-mediated DNA repair, and mitochondrial electron transport. Tissue NAD+ concentrations decline with age, a finding detailed in Verdin's 2015 Science review, with 2024-2026 mitochondrial-peptide reviews repeatedly pairing NAD+ precursors with MOTS-c when modelling mitochondrial recovery [6].

Researchers comparing copper-peptide extracellular matrix (ECM) effects against the BPC-157 / TB-500 structural-repair arm typically reference BPC-157 vs TB-500: recovery peptides compared, and those building a parallel dosing schedule use how to dose BPC-157 + TB-500 as the protocol template. Body Pharm UK supplies both GHK-Cu and NAD+ as dose-validated multi-dose pens to eliminate reconstitution variance across study arms.

How Body Pharm UK Sources and Validates Recovery Peptides

Body Pharm UK supplies recovery peptides as sealed, dose-validated multi-dose pens dispatched discreetly across the United Kingdom for laboratory research use only. Dose-validation means each pen is verified for concentration accuracy before release, so researchers comparing study arms (for example, BPC-157 against a BPC-157 + TB-500 blend) are not introducing reconstitution variance as a confounder. As of 2026, Body Pharm UK is the official UK source for Body Pharm peptide products.

What 'dose-validated' means in practice

Our pens are filled at a verified peptide concentration, sealed at manufacture, and traceable batch-to-batch from synthesis through to dispatch. Because the liquid is pre-validated rather than reconstituted by the end researcher, the per-click or per-unit volume corresponds to a known peptide mass. This matters most for peptides where the literature is thin on combination pharmacodynamics, such as the BPC-157 + TB-500 blend, which has no published controlled co-therapy trials as of 2026 [2][3].

Regulatory positioning

All Body Pharm UK products are supplied strictly for research and analytical purposes. They are not for human consumption, are not MHRA-licensed medicines, and carry no therapeutic claims, consistent with how UK research-peptide vendors are required to position BPC-157, TB-500, MOTS-c, GHK-Cu, and CJC-1295 / Ipamorelin in 2026 [8].

Researchers progressing from comparison to protocol typically move from BPC-157 vs TB-500: recovery peptides compared to how to dose BPC-157 + TB-500.

UK Regulatory Context: Research Peptides in 2026

None of the peptides covered in this guide hold MHRA marketing authorisation as licensed medicines for human use in the UK as of 2026. They are supplied lawfully for in vitro and laboratory research use only, which is the position UK research-peptide vendors are required to take to avoid making medicines claims [8].

The specifics matter for compliance documentation:

• BPC-157 and TB-500 are unlicensed investigational substances with no MHRA-approved indications and no completed Phase II/III human trials in the musculoskeletal space as of 2026 [2][3].
• MOTS-c is unlicensed in the UK; the foundational human data remains Lee et al. 2021 in Nature Metabolism, not yet replicated in large independent cohorts [11].
• CJC-1295 and Ipamorelin are unlicensed in the UK and, where supplied clinically at all, move through specialist clinics or imported "specials" rather than as MHRA-authorised products [7].
• GHK-Cu is regulated in the UK and EU as a cosmetic ingredient for topical use; there is no MHRA marketing authorisation for injectable GHK-Cu [8].
• NAD+ appears as a food supplement ingredient in some oral formulations but is supplied by research vendors as a research compound, not a medicine.

All six remain prohibited in-competition under WADA peptide hormone and growth factor rules, which UK sport bodies follow [1].

This section is not legal advice. Researchers, institutional buyers, and clinicians should consult a qualified UK regulatory or legal professional about their specific intended use, particularly where research crosses into human application or competitive sport. For mechanism-level comparison before any procurement decision, see BPC-157 vs TB-500: recovery peptides compared.

Frequently Asked Questions: Recovery Peptides UK

Q1: What is the best peptide for tendon and ligament repair research?

BPC-157 is the most-cited peptide in tendon and ligament repair research because rodent Achilles and medial collateral ligament transection models from the 2010s show accelerated fibroblast migration and collagen organisation, though no completed human Phase II/III musculoskeletal trials existed as of 2026 [2][3]. Researchers commonly pair it with TB-500 for systemic angiogenic support; see how to dose BPC-157 + TB-500.

Q2: What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid gastric pentadecapeptide acting locally on VEGFR2 and nitric oxide pathways, whereas TB-500 is a synthetic fragment of thymosin β4 acting systemically via actin sequestration and angiogenesis [2][3]. BPC-157 is faster-acting in localised injury models; TB-500 has a longer functional half-life. Full mechanism comparison: BPC-157 vs TB-500: recovery peptides compared.

Q3: Can MOTS-c be combined with BPC-157 in research?

MOTS-c can be co-administered with BPC-157 in research protocols because the two act on non-overlapping pathways: MOTS-c targets mitochondrial AMPK signalling per Lee et al. 2021 in Nature Metabolism [12], while BPC-157 targets local angiogenesis and cytoprotection [2]. No published combination study existed as of 2026, so any co-administration is hypothesis-driven rather than validated [13].

Q4: What does 'dose-validated multi-dose pen' mean?

A dose-validated multi-dose pen is a pre-filled peptide cartridge whose delivered dose per click has been verified at manufacture, so each increment matches what the researcher records. This removes the reconstitution-and-syringe error common with lyophilised vials, where actual delivered volume often deviates from intended dose.

Q5: Why pair CJC-1295 with Ipamorelin for recovery research?

CJC-1295 is paired with Ipamorelin because CJC-1295 (a GHRH analogue with DAC) sustains baseline GHRH tone, while Ipamorelin (a selective GHS-R agonist) triggers a discrete GH pulse without raising cortisol or prolactin in preclinical models [3][4]. The combination is studied for amplified pulsatile GH/IGF-1 release relevant to recovery endpoints [3].

Q6: Are recovery peptides legal to buy in the UK?

Recovery peptides such as BPC-157, TB-500, MOTS-c, CJC-1295 and Ipamorelin are legal to supply in the UK strictly as research chemicals for in vitro or laboratory use, because none hold MHRA marketing authorisation as medicines [8]. Sale for human administration is not permitted, and all five remain prohibited in-competition under WADA rules [1].

Next Steps

To match a peptide to your specific repair endpoint before purchase, start with the mechanism comparison at BPC-157 vs TB-500: recovery peptides compared, then move to how to dose BPC-157 + TB-500 to build the protocol, and order the corresponding dose-validated multi-dose pen from Body Pharm UK for dispatch across the United Kingdom.

References

1. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and instrument. J Orthop Res. 2006. pubmed.ncbi.nlm.nih.gov/16583442
2. Krivic A, et al. BPC-157 in tendon/ligament healing (rodent models); no published Phase II/III musculoskeletal RCT as of 2026. J Orthop Res. 2006. pubmed.ncbi.nlm.nih.gov/16583442
3. MHRA marketing-authorisation status and WADA prohibited-list classification for recovery peptides. Regulatory position; no single specific publication cited — unlinked.
4. Goldstein AL, et al. Thymosin β4 (TB-500 parent peptide): a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012. pubmed.ncbi.nlm.nih.gov/22074294
5. BPC-157 + TB-500 blend — mechanistic extrapolation; no peer-reviewed combination RCT published as of 2026. Absence-of-evidence note — unlinked.
6. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015. pubmed.ncbi.nlm.nih.gov/26785480
7. Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov/16352683
8. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. pubmed.ncbi.nlm.nih.gov/29986520
9. Absence of peer-reviewed BPC-157 + TB-500 combination trials and of Phase II/III human musculoskeletal RCTs for either peptide as of 2026. Absence-of-evidence note — unlinked.
10. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
11. Lee C, et al. MOTS-c and AMPK-linked metabolic regulation (foundational MOTS-c characterisation). Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
12. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
13. MHRA unlicensed status and UK cosmetic-only (topical) regulation of GHK-Cu; no MHRA authorisation for injectable use. Regulatory position — unlinked.